Alex Huang

Vice President, Head of Cell Therapy (member of the R&D Leadership Team) at BeiGene | United States

About Alex Huang

Alex Shihmin Huang serves as the Vice President and Head of Cell Therapy at BeiGene, where he plays a pivotal role in shaping the company’s strategic vision and operational framework within the rapidly evolving landscape of immuno-oncology. With over 20 years of experience in pharmaceutical R&D, Alex is driven by a commitment to multidisciplinary leadership that fosters collaboration across diverse scientific domains. His expertise in oncology, translational research, and drug development has been instrumental in establishing BeiGene’s iPSC-derived T cell therapy platforms, which are designed to address critical unmet needs in cancer treatment.

In his current role, Alex has successfully designed and led a dynamic research strategy that not only accelerates the path to clinical trials but also positions BeiGene competitively within the cell therapy market. Within just 24 months, he has implemented a roadmap that emphasizes innovative approaches to biomarker discovery and high-throughput screening, ensuring that the pipeline remains sustainable and aligned with the latest advancements in cancer research. His ability to oversee portfolio management while nurturing scientific talent exemplifies his dual focus on organizational impact and pipeline development.

As a member of the R&D Leadership Team, Alex is committed to fostering a culture of excellence and innovation, empowering his team to push the boundaries of what is possible in cell therapy. His strategic insights and hands-on leadership style not only enhance BeiGene's capabilities but also contribute to the broader mission of transforming cancer care through cutting-edge research and development.

Alex Huang Work